预约演示
更新于：2025-05-16
Pranlukast Hydrate
普仑司特
更新于：2025-05-16
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1995-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H25N5O5 |
InChIKeyBNGZNZUNROGDHT-UHFFFAOYSA-N |
CAS号150821-03-7 |
关联
22
项与 普仑司特 相关的临床试验CTR20231693
普仑司特干糖浆（70mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
NCT03826485
A Randomized, Open-label, Single-dose, Crossover Study to Compare Pharmacokinetics of PRIC and Pranlukast Dry Syrup in Healthy Male Volunteers
JPRN-UMIN000025608
A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infection - A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infection
100 项与 普仑司特 相关的临床结果
登录后查看更多信息
100 项与 普仑司特 相关的转化医学
登录后查看更多信息
100 项与 普仑司特 相关的专利（医药）
登录后查看更多信息
700
项与 普仑司特 相关的文献（医药）2025-04-01Journal of Allergy and Clinical Immunology-In Practice
Neuropsychiatric Events Related to Montelukast and Pranlukast in Adults With Asthma and Rhinitis: A 10-Year Nationwide Population-Based Study
Article
作者: Kwon, Hyouk-Soo ; Jo, Young-Woo ; Kwon, Jae-Woo ; Her, Young ; Min, Joonhong
BACKGROUND:
Epidemiological studies of neuropsychiatric events (NPEs) associated with leukotriene receptor antagonists (LTRAs) have yielded inconsistent results. Recent studies have demonstrated strong temporal relationships between LTRA prescription and NPE occurrence, indicating a need for further investigation.
OBJECTIVE:
To investigate potential LTRA-related NPEs and associated risk factors.
METHODS:
Adults with asthma or rhinitis were enrolled from the Korean claims database. The temporal relationship between the first NPE diagnosis and the last LTRA prescription before NPE was evaluated. Nested case-control studies for NPEs and suicide were conducted. Cases (those with NPEs) were matched to controls for age and sex to compare the frequency of LTRA prescription in the lag time before NPE diagnosis. The risk factors for LTRA-related NPEs (developed within 6 months of LTRA prescription) were assessed in people on LTRAs by comparing those with LTRA-related NPEs to those on LTRAs who did not have NPEs.
RESULTS:
Montelukast and pranlukast were more frequently prescribed within 6 months before NPEs (odds ratio, 1.31, 95% CI, 1.21-1.41, and odds ratio, 1.25, 95% CI, 1.15-1.35). Older adults, low income, high comorbidity burden, and asthma exhibited stronger associations with LTRA-related NPEs than with general NPEs. Sleep disturbances appeared more prevalent in LTRA-related NPEs than in other NPEs. An LTRA prescription within 6 months was associated with suicide in univariate but not in multivariate analysis.
CONCLUSIONS:
Increased neuropsychiatric risk was observed within 6 months after LTRA prescription. LTRA may lower the threshold for NPEs in those at risk for NPEs, irrespective of sex.
2025-03-01Liver International
Effects of Remote Ischemic Conditioning on Postoperative Recovery After Hepatectomy: A Randomised Controlled Trial
Article
作者: Guo, Qiao ; Tian, Hongni ; Chen, Jie ; Huang, He ; Duan, Guangyou ; Tian, Chun ; Li, Wenlang
ABSTRACT:
Background and Aims:
Remote ischemic conditioning (RIC) has shown promise in preclinical and clinical studies, but its effectiveness in reducing hepatic ischemia–reperfusion injuries (HIRIs) and enhancing postoperative recovery after hepatectomy remains uncertain. In this study, we aimed to evaluate the impact of perioperative RIC (PRIC) on postoperative recovery in patients undergoing hepatectomy.
Methods:
A randomised controlled trial was performed. A total of 135 eligible patients were randomised to either a control group (sham RIC), a PRIC‐1 group (RIC once daily for 3 days starting on the day of surgery) or a PRIC‐2 group (RIC twice daily). The primary outcome was the time to 2 times the upper limit of normal (2ULN) alanine transaminase (ALT) levels post‐hepatectomy. Secondary outcomes included time to reach 2ULN for aspartate transaminase (AST) levels, the area under the concentration–time curve on postoperative Day 7 (AUC‐POD7) for ALT, AST, total bilirubin and lactic acid, as well as assessments of gastrointestinal function and postoperative complications.
Results:
Median time to 2ULN ALT was shorter in the PRIC‐1 and PRIC‐2 groups than in the control group (PRIC‐1: 5.0 [3.5, 6.0] vs. control: 7.0 [7.0, 10.0] days, p < 0.001; PRIC‐2: 5.0 [4.0, 8.0] vs. control: 7.0 [7.0, 10.0] days, p < 0.001). The AUC‐POD7 for ALT and AST, time to 2ULN AST, time to gastrointestinal tolerance and postoperative complications were significantly improved in the PRIC groups compared with thecontrols.
Conclusions:
PRIC is safe and effective in reducing HIRIs and enhancing recovery post‐hepatectomy. Once‐daily PRIC offers similar benefits to twice‐daily PRIC.
Trial Registration:
NCT06130436 (ClinicalTrials.gov)
2025-03-01NEUROTOXICOLOGY
Therapeutic potential of pranlukast against cuprizone-induced inflammatory demyelination and sensory impairment in mice: Comparison with fingolimod
Article
作者: Dos Santos Heringer, Luiza ; Magalhães Portela, Débora ; de Pádua, Ana Carolina ; Espírito Santo Araújo, Sheila ; Cardoso, Ricardo ; Blanco Martinez, Ana Maria ; Miranda De Sá, Ana Beatriz ; Nascimento Pires, Greice ; Rocha Mendonça, Henrique ; Pereira Laurindo, Renata ; Calixto da Silva, Stefanny ; Batista Carneiro, Milena ; Alves Da Cruz, Saulo Augusto
Inflammatory demyelination is present in debilitating diseases such as Multiple Sclerosis (MS). Several drugs are available for MS treatment, with fingolimod as a first-line oral option in the United States. However, a cure has yet to be established, and therapeutic failures are common, highlighting the need for continued research into new pharmacological targets. Pranlukast has shown positive effects on myelination in cell cultures and after LPC-induced demyelination in mice, but it is not yet part of the therapeutic arsenal for this disease. This study investigates pranlukast's effect on demyelination protection in an MS animal model, compared to fingolimod. For this purpose, young adult Swiss mice were treated for five weeks with a 0.2 % cuprizone diet and received daily intraperitoneal injections of pranlukast (0.1 mg/kg), fingolimod (1 mg/kg), or vehicle. Pranlukast treatment, like fingolimod, partially preserved sensory function in the tactile sensitivity test. Both treatments partially preserved myelin basic protein (MBP) levels, but only fingolimod preserved lipids and myelinated fibers in the corpus callosum (CC) at all g-ratio ranges. Cuprizone and Pranlukast groups presented more microglia/macrophages in the CC, but fewer presenting reactive microglia/macrophages and less NOS2 staining in pranlukast-treated when compared to the cuprizone group, while fingolimod treatment prevented the increase in Iba1 in the CC. In summary, this study demonstrated that pranlukast is a good candidate as a novel drug for use in conditions of inflammatory demyelination, such as MS, by restoring function through modulation of the inflammatory environment.
100 项与 普仑司特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 韩国 | 2024-08-14 | |
| 过敏性鼻炎 | 日本 | 2000-01-08 | |
| 哮喘 | 日本 | 1995-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎 | 临床3期 | 日本 | 2006-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用